Effects of treatment with abiraterone acetate on body composition

Data from early Phase I/II clinical trials of abiraterone acetate in men with metastatic, castration-resistant prostate cancer (mCRPC) suggest that combining abiraterone acetate with dexamethasone limits loss of muscle mass and visceral fat. Low-dose dexamethasone was used rather than prednisone in these early clinical trials. … READ MORE …

Is possible new prostate cancer vaccine really “promising”?

A new article on the Medscape Oncology web site (and again correlated with a media release sent out by the European Association for Urology [EAU] from their annual meeting in Milan, Italy) is headed “Prostate cancer vaccine shows promise.” However, the degree of that “promise” appears to be open to some question. … READ MORE …

Friday’s news and reports: December 26, 2008

With at least a dozen new reports available today, we have chosen to focus only on the most significant, several of which may be of clinical importance now or in the near future. Most of the other items provide minimal new information and can be accessed through the UroToday web site by those who are interested. … READ MORE …